EcoDrugPlus

Dna Topoisomerase I

Ensembl ID : ENSDARG00000086775
Gene Symbol: TOP1
5 Cross references
201 Possible Orthologues:

Dna Topoisomerase I, Like

Ensembl ID : ENSDARG00000070545
Gene Symbol: TOP1L
5 Enzyme and pathways 5 Cross references
208 Possible Orthologues:

Dna Topoisomerase Ii Alpha

Ensembl ID : ENSDARG00000024488
Gene Symbol: TOP2A
5 Enzyme and pathways 5 Cross references
207 Possible Orthologues:

Dna Topoisomerase Ii Beta

Ensembl ID : ENSDARG00000034195
Gene Symbol: TOP2B
5 Enzyme and pathways 5 Cross references
209 Possible Orthologues:

Emap Like 4

Ensembl ID : ENSDARG00000109443
Gene Symbol: EML4
6 Cross references
212 Possible Orthologues:

F2r Like Thrombin Or Trypsin Receptor 3

Ensembl ID : ENSDARG00000079399
Gene Symbol: F2RL3
10 Enzyme and pathways 6 Cross references
191 Possible Orthologues:

Fau Ubiquitin Like And Ribosomal Protein S30 Fusion A

Ensembl ID : ENSDARG00000099022
Gene Symbol: FAUA
5 Cross references
300 Possible Orthologues:

Fau Ubiquitin Like And Ribosomal Protein S30 Fusion B

Ensembl ID : ENSDARG00000043663
Gene Symbol: FAUB
5 Cross references
240 Possible Orthologues:

Fyn Proto-Oncogene, Src Family Tyrosine Kinase A

Ensembl ID : ENSDARG00000011370
Gene Symbol: FYNA
54 Enzyme and pathways 5 Cross references
192 Possible Orthologues:

Fyn Proto-Oncogene, Src Family Tyrosine Kinase B

Ensembl ID : ENSDARG00000025319
Gene Symbol: FYNB
5 Cross references
201 Possible Orthologues:

G Protein-Coupled Receptor 84

Ensembl ID : ENSDARG00000077308
Gene Symbol: GPR84
7 Enzyme and pathways 5 Cross references
114 Possible Orthologues:

Hck Proto-Oncogene, Src Family Tyrosine Kinase

Ensembl ID : ENSDARG00000058647
Gene Symbol: HCK
5 Enzyme and pathways 5 Cross references
203 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).